drugset / Trial / NCT01639846
Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To purpose of this study is to establish the efficacy and safety of RX-10045 ophthalmic solution in alleviating the signs and symptoms of allergic conjunctivitis
Timeline
- Start
- 2012-07
- Primary completion
- 2012-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NAVAMEPENT | Small molecule | 0.09 % | Other |